Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.00 – $0.05
22% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $860.2K | $530.1K | $563.1K | $510.6K | $456.1K | $489.7K | $472.9K |
| Cost of revenue | $398.2K | $380.4K | $262.0K | $273.7K | $270.7K | $270.5K | $295.5K | $561.8K |
| Gross profit | $689.2K | $479.8K | $268.1K | $289.4K | $239.9K | $185.6K | $194.2K | −$88.9K |
| Gross margin | 63.4% | 55.8% | 50.6% | 51.4% | 47.0% | 40.7% | 39.7% | -18.8% |
| R&D | $880.8K | $535.5K | $431.2K | $995.4K | $681.8K | $586.1K | $526.3K | $499.6K |
| Operating income | −$4.1M | −$3.1M | −$3.0M | −$4.6M | −$3.9M | −$3.0M | −$2.3M | −$4.3M |
| EBITDA | −$4.0M | −$3.0M | −$3.1M | −$4.5M | −$3.8M | −$2.4M | −$2.3M | −$4.2M |
| Net income | −$4.2M | −$3.3M | −$3.2M | −$5.3M | −$5.1M | −$4.6M | −$3.7M | −$6.3M |
| Net margin | -385.0% | -380.9% | -603.6% | -945.4% | -1005.4% | -1004.3% | -746.0% | -1329.2% |
| EPS (diluted) | -0.03 | -0.02 | -0.02 | -0.03 | -0.03 | -0.02 | -0.01 | -0.02 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $3M | $-0.02 | $-0.02–$-0.02 | 1 |
| 2027 | $11M | $0.01 | $0.01–$0.01 | 1 |
| 2028 | $19M | $0.03 | $0.03–$0.03 | 1 |
Forward consensus · source: Financial Modeling Prep
MEDX HEALTH CORP
No one on the platform currently holds MDXHF.
No tracked institution reports a position in MDXHF as of their last filing.
No one on the platform has traded MDXHF yet.
| $1072 |
| — |
| NICXFNicox S.A. | $0.30 | +0.00% | $31M | — |
| PCNEFPrecision System Science Co., Ltd. | $2.28 | +0.00% | $62M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 6.4× sales vs its 19.3× historical median P/S.
Fair value ≈ $0.04 · price $0.01 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.